MX369477B - Formulaciones farmacéuticas de estatinas y ácidos grasos omega-3 para encapsulación. - Google Patents

Formulaciones farmacéuticas de estatinas y ácidos grasos omega-3 para encapsulación.

Info

Publication number
MX369477B
MX369477B MX2012013933A MX2012013933A MX369477B MX 369477 B MX369477 B MX 369477B MX 2012013933 A MX2012013933 A MX 2012013933A MX 2012013933 A MX2012013933 A MX 2012013933A MX 369477 B MX369477 B MX 369477B
Authority
MX
Mexico
Prior art keywords
phase
omega
fatty acids
dosage form
statins
Prior art date
Application number
MX2012013933A
Other languages
English (en)
Other versions
MX2012013933A (es
Inventor
Draper Peter
Okutan Beth
Draper James
Original Assignee
Accucaps Industries Ltd Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accucaps Industries Ltd Star filed Critical Accucaps Industries Ltd Star
Publication of MX2012013933A publication Critical patent/MX2012013933A/es
Publication of MX369477B publication Critical patent/MX369477B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Jellies, Jams, And Syrups (AREA)

Abstract

Una forma de dosificación de gelatina blanda de múltiples fases que comprende por lo menos una forma de dosificación sólida preformada que comprende un compuesto de estatina y por lo menos una fase de relleno líquida que comprende ácidos grasos Omega-3. Las formas de dosificación de gelatina blanda de múltiples fases de la presente invención son especialmente útiles para combinar por lo menos una forma de dosificación sólida y por lo menos una fase líquida para una sola ingestión. La fase sólida, la fase líquida o los recubrimientos además pueden comprender ingredientes farmacéuticos activos, nutracéuticos, suplementos nutricionales, o sustancias terapéuticas, excipientes convencionales o combinaciones de los mismos.
MX2012013933A 2010-06-03 2011-06-03 Formulaciones farmacéuticas de estatinas y ácidos grasos omega-3 para encapsulación. MX369477B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2706270A CA2706270C (en) 2010-06-03 2010-06-03 Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation
PCT/CA2011/000650 WO2011150505A1 (en) 2010-06-03 2011-06-03 Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation

Publications (2)

Publication Number Publication Date
MX2012013933A MX2012013933A (es) 2013-02-11
MX369477B true MX369477B (es) 2019-11-08

Family

ID=45066009

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012013933A MX369477B (es) 2010-06-03 2011-06-03 Formulaciones farmacéuticas de estatinas y ácidos grasos omega-3 para encapsulación.
MX2019013095A MX2019013095A (es) 2010-06-03 2012-11-29 Formulaciones farmaceuticas de estatinas y acidos grasos omega-3 para encapsulacion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019013095A MX2019013095A (es) 2010-06-03 2012-11-29 Formulaciones farmaceuticas de estatinas y acidos grasos omega-3 para encapsulacion.

Country Status (12)

Country Link
US (2) US11975108B2 (es)
EP (2) EP2575787B1 (es)
JP (2) JP5972261B2 (es)
AU (1) AU2011261117B2 (es)
CA (1) CA2706270C (es)
DK (1) DK2575787T3 (es)
ES (1) ES2807498T3 (es)
HU (1) HUE050830T2 (es)
MX (2) MX369477B (es)
PL (1) PL2575787T3 (es)
PT (1) PT2575787T (es)
WO (1) WO2011150505A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014095628A1 (en) * 2012-12-17 2014-06-26 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Oral formulation containing a statin in omega-3 polyunsaturated fatty acids (n-3 pufa)
CA2926335C (en) 2013-10-30 2021-11-23 Banner Life Sciences Llc Enteric soft capsules comprising polyunsaturated fatty acids
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326965B2 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
WO2015185240A1 (en) 2014-06-04 2015-12-10 Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. Compositions containing simvastatin in omega-3 polyunsaturated fatty acids
US9895333B2 (en) 2014-06-26 2018-02-20 Patheon Softgels Inc. Enhanced bioavailability of polyunsaturated fatty acids
CA2950444C (en) * 2014-06-26 2021-01-12 Banner Life Sciences Llc Enhanced bioavailability of polyunsaturated fatty acids
CN106794149A (zh) * 2014-08-13 2017-05-31 韩国联合制药株式会社 含ω‑3脂肪酸酯和他汀类的口服给药复合制剂
KR101950907B1 (ko) * 2016-02-05 2019-02-21 한국유나이티드제약 주식회사 지용성 약물 및 방유성 기제가 코팅된 고형제제를 포함하는 경구용 복합제제
WO2017171484A1 (ko) * 2016-03-31 2017-10-05 한미약품 주식회사 오메가-3 지방산 또는 이의 에스테르, 및 하이드록시메틸글루타릴 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
US11547693B2 (en) 2019-07-29 2023-01-10 Matthias Rath Ascorbate in the prevention of statin induced vascular calcification
US10736872B1 (en) * 2019-09-05 2020-08-11 Matthias W. Rath Pharmaceutical mixture to treat statin induced vascular calcification
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
EP4185277A4 (en) * 2020-07-23 2024-08-07 Procaps Sa SOFT-SHELL GELATIN CAPSULES
BR102021011153B1 (pt) 2021-06-09 2022-12-27 Fernando Campos Barbosa Composição fitoterápica associada a suplementos polivitamínicos e minerais

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1803440A (en) * 1929-07-25 1931-05-05 Newspaper Mechanical Sales Com Coin control for vending machines
US2775080A (en) 1950-05-26 1956-12-25 American Cyanamid Co Method of forming powder-and-liquid filled capsules
US2711814A (en) * 1953-08-14 1955-06-28 Bartlett And Company Grain Apparatus for cleaning flat bottom grain tanks
US3536074A (en) 1968-03-29 1970-10-27 Alfred Aufhauser Oral administration of a pill,tablet or capsule
US4655027A (en) 1980-11-24 1987-04-07 Chasman Sydney A Method and apparatus for forming capsules
JPH08511559A (ja) * 1993-06-18 1996-12-03 スミスクライン・ビーチャム・コーポレイション 軟外皮ゼラチンに封入された粒子
EP1792616B1 (en) * 1997-07-31 2009-12-16 Abbott Respiratory LLC Composition comprising an HMG-CoA inhibitor and a nicotinic acid compound for treating hyperlipidemia
US6238616B1 (en) 1998-12-14 2001-05-29 Timecaps Inc. Method of manufacturing gelatin capsule containing powder or time release pellets
US6574945B2 (en) 2001-03-21 2003-06-10 Lumitek Llc Method for manufacturing a projectile containing chemiluminescent compounds
ATE358477T1 (de) * 2001-06-12 2007-04-15 Galephar M F Oral anzuwendende arzneizusammensetzung enthaltend ein statinderivat
WO2004000731A2 (en) 2002-06-25 2003-12-31 Akzo Nobel N.V. Use of cationic layered materials, compositions comprising these materials, and the preparation of cationic layered materials
FR2850275B1 (fr) * 2003-01-24 2005-04-08 Scherer Technologies Inc R P Capsules molles a macher contenant une substance active a gout masque
US20040146537A1 (en) * 2003-01-28 2004-07-29 Ramachandran Radhakrishnan Oily wax matrix suspension formulation comprising pharmacologically active agents
CA2475765A1 (en) 2003-07-29 2005-01-29 L. Perrigo Company Tablet encapsulating machine
CN101318923A (zh) * 2003-09-17 2008-12-10 沃尼尔·朗伯有限责任公司 [R－(R*,R*)]－2－(4－氟苯基)－β,δ－二羟基－5－(1－甲基乙基)－3－苯基－4－[(苯基氨基)羰基]－1H－吡咯－1－庚酸的结晶形式
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
US20070191467A1 (en) * 2004-12-06 2007-08-16 Reliant Pharmaceutical, Inc. Statin and omega-3 fatty acids for lipid therapy
EA200701913A1 (ru) * 2005-03-08 2008-08-29 Релайэнт Фармасьютикалз, Инк. Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом
US7887852B2 (en) * 2005-06-03 2011-02-15 Soft Gel Technologies, Inc. Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
WO2006136196A1 (en) * 2005-06-21 2006-12-28 V. Mane Fils Gellan seamless breakable capsule and process for manufacturing thereof
ES2511772T3 (es) * 2005-12-20 2014-10-23 Cenestra, Llc Formulaciones de ácidos grasos omega-3
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
WO2007103557A2 (en) * 2006-03-09 2007-09-13 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
US20070218141A1 (en) * 2006-03-15 2007-09-20 Ashis Kumar Mehta Simvastatin compositions
US20100310650A1 (en) * 2006-06-26 2010-12-09 Roberto Valducci Pharmaceutical composition for the oral administration of omega polyenoic fatty acids and one or more active principles incompatible therewith, and a process for its preparation
EP2431043A1 (en) * 2007-05-23 2012-03-21 Amcol International Corporation Cholesterol-interacting layered phyllosilicates for suppressing gastrointestinal cholesterol absorption
ITMI20072142A1 (it) * 2007-11-08 2009-05-09 Yervant Zarmanian Composizioni farmaceutiche contenenti statine e derivati di acidi grassi omega-3
EP2455070A1 (en) * 2008-01-10 2012-05-23 Takeda Pharmaceutical Company Limited Capsule Formulation
WO2009151116A1 (ja) * 2008-06-13 2009-12-17 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
US20100062057A1 (en) * 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
GB0818472D0 (en) * 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
CA3065589C (en) * 2010-06-03 2022-04-26 Catalent Ontario Limited Multi phase soft gel capsules, apparatus and method thereof

Also Published As

Publication number Publication date
EP2575787B1 (en) 2020-05-27
HUE050830T2 (hu) 2021-01-28
EP2575787A4 (en) 2013-11-27
JP2016138143A (ja) 2016-08-04
US20230233472A1 (en) 2023-07-27
MX2019013095A (es) 2020-01-30
AU2011261117A1 (en) 2012-12-13
JP5972261B2 (ja) 2016-08-17
AU2011261117B2 (en) 2015-08-13
CA2706270A1 (en) 2011-12-03
EP3581173A1 (en) 2019-12-18
DK2575787T3 (da) 2020-08-03
CA2706270C (en) 2020-01-07
WO2011150505A1 (en) 2011-12-08
PT2575787T (pt) 2020-07-28
US11975108B2 (en) 2024-05-07
MX2012013933A (es) 2013-02-11
PL2575787T3 (pl) 2020-11-02
EP2575787A1 (en) 2013-04-10
US20130115281A1 (en) 2013-05-09
JP2013527205A (ja) 2013-06-27
EP3581173B1 (en) 2024-08-28
ES2807498T3 (es) 2021-02-23

Similar Documents

Publication Publication Date Title
MX2019013095A (es) Formulaciones farmaceuticas de estatinas y acidos grasos omega-3 para encapsulacion.
EP4327797A3 (en) Multi phase soft gel capsules, apparatus and method thereof
NZ600720A (en) A Seamless Capsule For A Liquid Pharmaceutical Composition
EA201290982A1 (ru) Фармацевтические композиции, препятствующие злоупотреблению
WO2011060945A3 (en) Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases
WO2012013331A3 (en) Capsules of active pharmaceutical ingredients and polyunsaturated fatty acids for the treatment of prostate diseases
WO2011124953A3 (en) Controlled release pharmaceutical compositions of tapentadol
MX340591B (es) Formulaciones de liberacion inmediata y formas de dosis de gamma-hidroxibutirato.
WO2009098520A3 (en) Composition and method for assisting swallowing
WO2012085671A3 (en) Antioxidants in fish oil powder and tablets
WO2011060944A3 (en) Active pharmaceutical ingredient capsules and polyunsaturated fatty acid esters
WO2009118359A3 (en) Capsule for the prevention of cardiovascular diseases
EP3658124A4 (en) COMPOSITIONS FOR INCREASING THE BIOAVAILABILITY OF MEDICINAL PRODUCTS, SUPPLEMENTS AND INGESTED SUBSTANCES
PL3793534T3 (pl) Tabletka doustna do dostarczania składników czynnych do przewodu żołądkowo-jelitowego
EP3279210A4 (en) Peptide having anticancer activity, and pharmaceutical composition and dietary supplement composition for preventing and treating cancer, both of which contain same as active ingredient
WO2006109194A3 (en) Chromium-fatty acid compounds and methods of making and using thereof
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
PL1744733T3 (pl) Kompozycje farmaceutyczne zamknięte w miękkich kapsułkach żelowych zawierające stężone składniki czynne
JP2013540133A5 (es)
WO2007120838A3 (en) Rapidly disintegrating solid oral dosage form of liquid dispersions
EP4180048A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING A CER COMPOUND AS ACTIVE INGREDIENT
WO2012064130A3 (ko) 대장 선택성 셀레콕시브 전구체 화합물 및 이를 유효성분으로 함유하는 대장성 질환 치료 또는 예방용 약학조성물
WO2012007758A3 (en) Pharmaceutical formulations
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
DK2091520T3 (da) Oral doseringsform omfattende trisubstituerede glycerol-forbindelser

Legal Events

Date Code Title Description
FG Grant or registration